Menu Search
Equities

Siemens Healthineers AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SHL:STU

Siemens Healthineers AG

Actions
  • Price (EUR)46.01
  • Today's Change-0.61 / -1.31%
  • Shares traded7.86k
  • 1 Year change-15.33%
  • Beta0.6653
Data delayed at least 15 minutes, as of Jul 18 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Siemens Healthineers AG is a Germany-based company. The Company is a global provider of healthcare products, solutions and services. It also provides clinical consulting services and training and service offerings. The Company’s segments include Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers a software solutions to support the reading and structured reporting of diagnostic images from different modalities. The Diagnostics segment offers to healthcare providers in the fields of general laboratory, specialty laboratory, and point-of-care diagnostics. The Varian segment offers a portfolio of cancer care technologies and services and support oncology departments in hospitals and clinics. The Advanced Therapies segment consists of integrated products, services and solutions used in the treatment of diseases across multiple clinical fields.

  • Revenue in EUR (TTM)23.14bn
  • Net income in EUR2.09bn
  • Incorporated2017
  • Employees73.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SHLX:GER since
announced		Transaction
value
Novartis AG-Radiopharmaceutical BusinessDeal completed25 Aug 202425 Aug 2024Deal completed-10.29%--
Data delayed at least 15 minutes, as of Jul 18 2025 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.